# OnCo record rejuv-second-platinum-and-parp-inhibitors (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-platinum-and-parp-inhibitors" ;
  schema:name "Platinum drugs and PARP inhibitors: the newer leukaemia risk"@en ;
  schema:alternateName "PARP inhibitor MDS risk"@en, "Platinum-related myeloid neoplasm"@en, "Lenalidomide second primary malignancy"@en ;
  schema:description "The leukaemia risk after chemotherapy was described in the era of mustards and etoposide, and it did not stay there. Platinum drugs carry it, PARP inhibitors raise it about two and a half times against placebo, and lenalidomide with oral melphalan raises it nearly fivefold against melphalan alone. The absolute numbers are small, but the choice of partner drug is sometimes a real decision."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PARP_inhibitor> ;
  schema:citation <https://doi.org/10.1016/S2352-3026(20)30360-4>, <https://doi.org/10.1016/S1470-2045(13)70609-0>, <https://doi.org/10.1001/jamaoncol.2018.5625>, <https://doi.org/10.1182/blood-2012-08-448068> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "blood", "targeted-therapy" ;
  onco:related <https://onco.cc/terms/rejuv-second-cancers-overview/>, <https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/>, <https://onco.cc/terms/rejuv-second-choices-made-at-treatment/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/esophageal/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> .